Marksans Pharma Limited (NSE: MARKSANS)

Marksans Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	6,566	4,033	3,824	2,064	2,122	937.27
Short-Term Investments	153.94	2,710	3,328	1,399	-	-
Trading Asset Securities	-	269.94	5.4	4.35	2.61	-
Cash & Short-Term Investments	6,720	7,013	7,158	3,467	2,124	937.27
Cash Growth	1.65%	-2.03%	106.47%	63.19%	126.66%	179.46%
Accounts Receivable	5,525	4,532	4,168	3,948	2,719	2,434
Other Receivables	145.72	106.62	48.5	43.7	1.02	-
Receivables	5,670	4,638	4,217	3,991	2,721	2,434
Inventory	7,584	6,179	4,847	4,244	4,043	2,418
Prepaid Expenses	-	251.26	198.04	159.83	-	-
Other Current Assets	810.74	543.05	332.57	149.34	140.04	146.66
Total Current Assets	20,785	18,625	16,753	12,012	9,028	5,936
Property, Plant & Equipment	6,861	6,811	3,869	3,423	2,540	2,300
Long-Term Investments	-	1.68	-	-	-	-
Goodwill	409.44	394.99	384.89	300.25	195.86	243.76
Other Intangible Assets	713.75	647.62	707.97	585.69	474.36	483.27
Long-Term Deferred Tax Assets	-	-	-	38.57	7.99	6.34
Other Long-Term Assets	343.98	329.41	189.13	41.62	41.58	57.29
Total Assets	29,113	26,810	21,904	16,401	12,288	9,027
Accounts Payable	2,816	2,683	2,306	2,001	1,687	1,103
Accrued Expenses	18.46	442.56	220.96	131.01	103.53	77.89
Short-Term Debt	240.35	290.91	415.88	362.92	187.4	188.43
Current Portion of Long-Term Debt	-	-	-	50	-	0.46
Current Portion of Leases	191.11	249.51	156.68	280.52	60.37	32.41
Current Income Taxes Payable	308.27	199.08	252.78	173.27	300.21	118.57
Other Current Liabilities	866.77	33.66	57.59	563.67	651.52	766.5
Total Current Liabilities	4,441	3,898	3,410	3,562	2,990	2,288
Long-Term Debt	-	-	-	-	50	50
Long-Term Leases	1,551	1,900	656.89	414.34	93.26	75.2
Long-Term Deferred Tax Liabilities	25.59	106.2	153.86	176.21	80.63	107.94
Other Long-Term Liabilities	43.56	6.63	9.3	2.83	6.94	3.23
Total Liabilities	6,062	5,950	4,253	4,171	3,235	2,535
Common Stock	453.16	453.16	453.16	409.31	409.31	409.31
Additional Paid-In Capital	-	5,045	5,045	1,732	1,751	1,751
Retained Earnings	-	13,827	10,913	8,230	6,487	3,988
Comprehensive Income & Other	22,361	1,326	1,040	1,651	217.68	211.05
Total Common Equity	22,814	20,651	17,452	12,023	8,865	6,360
Minority Interest	237.21	208.52	199.1	207.01	188.57	131.1
Shareholders' Equity	23,051	20,859	17,651	12,230	9,054	6,491
Total Liabilities & Equity	29,113	26,810	21,904	16,401	12,288	9,027
Total Debt	1,983	2,441	1,229	1,108	391.03	346.5
Net Cash (Debt)	4,737	4,572	5,929	2,359	1,733	590.77
Net Cash Growth	-13.87%	-22.88%	151.30%	36.10%	193.41%	-
Net Cash Per Share	10.45	10.09	14.27	5.76	4.23	1.44
Filing Date Shares Outstanding	454.07	453.16	453.16	409.31	409.31	409.31
Total Common Shares Outstanding	454.07	453.16	453.16	409.31	409.31	409.31
Working Capital	16,344	14,726	13,343	8,450	6,039	3,648
Book Value Per Share	50.24	45.57	38.51	29.37	21.66	15.54
Tangible Book Value	21,691	19,608	16,359	11,137	8,195	5,633
Tangible Book Value Per Share	47.77	43.27	36.10	27.21	20.02	13.76
Land	-	5.18	5.1	4.67	4.14	4.14
Buildings	-	2,287	1,633	1,511	1,318	1,259
Machinery	-	4,445	3,355	3,038	2,515	2,237
Construction In Progress	-	53.81	72.46	6.95	56	-
Leasehold Improvements	-	105.64	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.